更新于：2024-09-07
Imidafenacin
咪达那新
更新于：2024-09-07
概要
基本信息
药物类型 小分子化药 |
别名 Imidafenacin (JAN/INN)、KRP 197、KRP-197 + [9] |
作用机制 M1 receptor拮抗剂(毒蕈碱型乙酰胆碱受体M1拮抗剂)、M3 receptor拮抗剂(毒蕈碱型乙酰胆碱受体M3拮抗剂) |
治疗领域 |
非在研适应症- |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (2007-04-18), |
最高研发阶段(中国)临床1期 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C20H21N3O |
InChIKeySQKXYSGRELMAAU-UHFFFAOYSA-N |
CAS号170105-16-5 |
关联
47
项与 咪达那新 相关的临床试验A randomized, open-label, two-formulation, two-period, crossover study of the bioequivalence of a single oral dose of Imidafenacin tablets in fasted and fed healthy Chinese subjects
咪达那新片（0.1mg）在中国健康人群中空腹和餐后状态下单次给药的人体生物等效性临床试验
Combined effect of vibegron and imidafenacin for OAB
100 项与 咪达那新 相关的临床结果
登录后查看更多信息
100 项与 咪达那新 相关的转化医学
登录后查看更多信息
100 项与 咪达那新 相关的专利（医药）
登录后查看更多信息
105
项与 咪达那新 相关的文献（医药）2023-05-01Lower urinary tract symptoms
Efficacy and safety of vibegron compared with mirabegron for overactive bladder: A systematic review and network meta‐analysis
Review
作者: He, Wenjuan ; Zhang, Yuqian ; Sun, Qian ; Liu, Xiuju ; Huang, Guangliang ; Tian, Yunfei
Abstract:
Objectives:
The aim of this study was to indirectly compare the efficacy and safety of mirabegron and vibegron in patients with overactive bladder.
Methods:
A systematic search was performed on Pubmed, Web of Science, Embase, and the Cochrane Central Register of Controlled Trials databases to identify studies from the date of database inception to January 1, 2022. All randomized controlled trials comparing mirabegron or vibegron with tolterodine, imidafenacin, or placebo were eligible. One reviewer extracted data, and a second reviewer checked. Included trials were assessed for similarity, and networks were developed using Stata 16.0 software. Mean differences for continuous variables and odds ratios for dichotomous variables together with their 95% confidence intervals (CIs) were used to rank treatments and compare the differences, respectively.
Results:
A total of 11 randomized controlled trials and 10 806 patients were included. For each outcome, results for all licensed treatment doses were included. Both vibegron and mirabegron were more efficacious than placebo at reducing the frequency of micturition, incontinence, urgency, urgency incontinence, and nocturia. Vibegron was more efficacious than mirabegron in reducing mean voided volume/micturition (95% CI [5.15, 14.98]). Safety outcomes for vibegron and mirabegron were similar to those in the placebo group, except for mirabegron, which had a higher risk of nasopharyngitis and cardiovascular adverse events than placebo.
Conclusions:
Both drugs seem to be comparable and well tolerated, particularly as direct comparisons are not available. However, vibegron may be more effective than mirabegron in reducing mean voided volume.
2021-10-01International urogynecology journal3区 · 医学
A systematic review of neurocognitive dysfunction with overactive bladder medications
3区 · 医学
Review
作者: Iglesia, Cheryl ; Iwamoto, Aya ; Duong, Vi ; Kudish, Bela ; Pennycuff, Jon
INTRODUCTION AND HYPOTHESIS:
The aim of this study is to report cognitive dysfunction with commonly used antimuscarinic overactive bladder medications in patients suffering from overactive bladder disorder with and without baseline neurologic conditions.
METHODS:
We conducted an Ovid MEDLINE, Embase, and PsycINFO search from January 1998 to December 2018 using PRISMA guidelines. Eighteen studies met the inclusion criteria, including 5 randomized controlled trials and 13 observational studies.
RESULTS:
Cognitive decline was reported with oxybutynin use (5 of 8 studies) and tolterodine use (4 of 7 studies) among patients with and without baseline cognitive impairment. Oxybutynin use was linked to functional, mental, and behavioral decline among patients with Alzheimer's disease (2 studies). No cognitive decline was detected among patients with and without baseline cognitive impairment taking trospium (6 studies), darifenacin (3 studies), imidafenacin (2 studies), and fesoterodine (1 study). Solifenacin was not associated with cognitive decline (2 studies) but was linked to an increased risk of dementia among patients with diabetes (1 study).
CONCLUSION:
In this review, cognitive decline was reported with oxybutynin and tolterodine use and should be used with caution in adults over 65 years of age. Solifenacin, fesoterodine, and imidafenacin showed mixed results related to central nervous system effect. Trospium and darifenacin were not associated with cognitive decline among patients with and without baseline cognitive impairment.
2021-09-01The Journal of international medical research4区 · 医学
Comparisons of the therapeutic safety of seven oral antimuscarinic drugs in patients with overactive bladder: a network meta-analysis
4区 · 医学
ArticleOA
作者: Xu, Faren ; Yang, Nannan ; Wu, Qiaoyan ; Zhang, Xiaopeng
Objectives:
This network meta-analysis aimed to assess the safety profiles of seven commonly used oral antimuscarinic drugs (darifenacin, fesoterodine, imidafenacin, oxybutynin, propiverine, solifenacin, and tolterodine) in patients with overactive bladder (OAB).
Methods:
PubMed, Cochrane Library, EMBASE, CNKI, and Wanfang databases were searched for randomized controlled trials (RCTs). Studies comparing one or more antimuscarinic drugs for treating OAB with reported adverse effects (AEs) were eligible. Data were extracted, and a network meta-analysis was performed by two authors independently.
Results:
Forty-five RCTs and 124,587 patients were included. The results demonstrated that tolterodine had better safety outcomes for 7 out of 12 major AEs, including dry mouth, constipation, urinary retention, dizziness, urinary tract infection, dry eyes, and dry skin. Darifenacin, fesoterodine, imidafenacin, oxybutynin, and solifenacin presented comparable safety profiles.
Conclusions:
Tolterodine may be preferable as it showed a reduced association with important AEs. Darifenacin, fesoterodine, imidafenacin, oxybutynin, and solifenacin have similar safety profiles in treating patients with OAB. Taken together, this analysis provides a valuable overview of the therapeutic safety for oral antimuscarinic drugs and is useful for personalized medicine in patients with OAB. Trial registration: This trial was retrospectively registered at INPLASY ( https://inplasy.com/ ) with the registration number 202170095.
1
项与 咪达那新 相关的新闻（医药）2024-01-15
·信狐药迅
100 项与 咪达那新 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 膀胱过度活动症 | 日本 | 2007-04-18 | |
| 膀胱过度活动症 | 日本 | 2007-04-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 尿频 | 申请上市 | 俄罗斯 | 2022-01-30 | |
| 急迫性尿失禁 | 临床1期 | 中国 | 2015-06-17 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 300 | 夢鬱觸網遞窪夢積窪遞(鏇糧築鏇選顧積遞淵膚) = 構範蓋製鏇夢構構壓願 遞襯鹽膚餘膚積窪蓋壓 (獵齋鑰積窪獵鹹網襯廠, 2.2) 更多 | 非劣 | 2019-06-01 | |||
夢鬱觸網遞窪夢積窪遞(鏇糧築鏇選顧積遞淵膚) = 願願觸壓築觸簾壓積簾 遞襯鹽膚餘膚積窪蓋壓 (獵齋鑰積窪獵鹹網襯廠, 1.8) 更多 | |||||||
临床3期 | 300 | (Uritos®) | 鹹積窪製蓋餘鑰淵鬱醖(餘觸鹹簾鏇蓋醖築獵遞) = 願鏇鬱齋齋獵願構鏇膚 顧壓壓鑰鬱構艱衊廠製 (夢餘製蓋簾網網膚選鬱, 網製廠鏇憲餘衊膚願艱 ~ 選製鏇蓋積壓積鏇廠積) 更多 | - | 2019-05-21 | ||
(Urotol®) | 鹹積窪製蓋餘鑰淵鬱醖(餘觸鹹簾鏇蓋醖築獵遞) = 夢餘淵襯選襯簾鑰鬱壓 顧壓壓鑰鬱構艱衊廠製 (夢餘製蓋簾網網膚選鬱, 築積範築網鹽襯壓壓鏇 ~ 製壓範膚選壓壓顧廠廠) 更多 | ||||||
临床4期 | 649 | (Mirabegron + Solifenacin) | 醖壓膚窪積壓鬱艱艱醖(窪繭鬱淵構鹹衊廠淵淵) = 夢醖簾艱窪鑰獵鹹選鏇 艱網膚範餘遞艱鬱廠願 (製願願膚觸觸艱願獵膚, 餘夢淵願選鹹憲願夢積 ~ 鹹壓製願廠襯膚製獵選) 更多 | - | 2018-12-24 | ||
(Mirabegron + Propiverine) | 醖壓膚窪積壓鬱艱艱醖(窪繭鬱淵構鹹衊廠淵淵) = 憲膚獵窪壓蓋醖遞糧範 艱網膚範餘遞艱鬱廠願 (製願願膚觸觸艱願獵膚, 餘範蓋糧鹽築鹹鑰網淵 ~ 膚顧齋觸構餘夢壓選選) 更多 | ||||||
N/A | 追加 | 308 | 膚鬱餘廠繭憲鏇繭鬱積(齋簾衊襯糧淵繭蓋繭餘) = 鹹願觸壓艱蓋積廠艱醖 醖鑰窪築窪膚鏇範糧構 (獵遞積夢範鑰淵廠顧範, 1.47 ~ 2.74) 更多 | 积极 | 2013-10-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用